HK1257882A1 - 通過t細胞療法來治療多發性骨髓瘤和漿細胞性白血病的方法 - Google Patents

通過t細胞療法來治療多發性骨髓瘤和漿細胞性白血病的方法

Info

Publication number
HK1257882A1
HK1257882A1 HK19100243.4A HK19100243A HK1257882A1 HK 1257882 A1 HK1257882 A1 HK 1257882A1 HK 19100243 A HK19100243 A HK 19100243A HK 1257882 A1 HK1257882 A1 HK 1257882A1
Authority
HK
Hong Kong
Prior art keywords
methods
multiple myeloma
treating multiple
cell therapy
cell leukemia
Prior art date
Application number
HK19100243.4A
Other languages
English (en)
Inventor
科伊內 岡瑟
Original Assignee
紀念斯隆-凱特林癌症中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 紀念斯隆-凱特林癌症中心 filed Critical 紀念斯隆-凱特林癌症中心
Publication of HK1257882A1 publication Critical patent/HK1257882A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464452—Transcription factors, e.g. SOX or c-MYC
    • A61K39/464453—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
HK19100243.4A 2015-09-10 2019-01-08 通過t細胞療法來治療多發性骨髓瘤和漿細胞性白血病的方法 HK1257882A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US201562220641P 2015-09-18 2015-09-18
PCT/US2016/050857 WO2017044678A1 (en) 2015-09-10 2016-09-09 Methods of treating multiple myeloma and plasma cell leukemia by t cell therapy

Publications (1)

Publication Number Publication Date
HK1257882A1 true HK1257882A1 (zh) 2019-11-01

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100243.4A HK1257882A1 (zh) 2015-09-10 2019-01-08 通過t細胞療法來治療多發性骨髓瘤和漿細胞性白血病的方法

Country Status (14)

Country Link
US (1) US20190381098A1 (zh)
EP (1) EP3347028A1 (zh)
JP (1) JP6947720B2 (zh)
KR (1) KR20180048992A (zh)
CN (1) CN108348552A (zh)
AU (1) AU2016320877A1 (zh)
CA (1) CA2997757A1 (zh)
HK (1) HK1257882A1 (zh)
IL (1) IL257929B2 (zh)
MX (1) MX2018002816A (zh)
RU (1) RU2743381C2 (zh)
TW (1) TWI759270B (zh)
WO (1) WO2017044678A1 (zh)
ZA (1) ZA201801656B (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200157502A1 (en) 2017-05-25 2020-05-21 Memorial Sloan Kettering Cancer Center Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
US11925663B2 (en) 2017-10-23 2024-03-12 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
WO2019178170A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1103564T3 (da) * 1998-07-31 2009-05-11 Int Inst Cancer Immunology Inc Cancerantigener baseret på tumorsuppressorgen WT1-produkt
ES2310052T3 (es) * 1998-09-30 2008-12-16 Corixa Corporation Composiciones y metodos para la inmunoterapia especifica de wt1.
CN101580538B (zh) * 2003-11-05 2013-06-19 株式会社国际癌症免疫研究所 Wt1衍生的hla-dr-结合抗原肽
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
ES2615861T3 (es) * 2008-10-30 2017-06-08 Yeda Research And Development Company Ltd. Células T de memoria central anti-terceros, métodos de producción de las mismas y uso de las mismas en trasplante y tratamiento de enfermedades
EP2802347B1 (en) * 2012-01-13 2019-01-09 Memorial Sloan Kettering Cancer Center Immunogenic wt-1 peptides and methods of use thereof

Also Published As

Publication number Publication date
RU2018112526A3 (zh) 2020-01-31
IL257929B2 (en) 2024-06-01
TW201714619A (zh) 2017-05-01
JP6947720B2 (ja) 2021-10-13
RU2743381C2 (ru) 2021-02-17
MX2018002816A (es) 2018-06-08
US20190381098A1 (en) 2019-12-19
JP2018530534A (ja) 2018-10-18
AU2016320877A1 (en) 2018-04-19
EP3347028A1 (en) 2018-07-18
WO2017044678A1 (en) 2017-03-16
CA2997757A1 (en) 2017-03-16
IL257929B1 (en) 2024-02-01
KR20180048992A (ko) 2018-05-10
ZA201801656B (en) 2022-12-21
RU2018112526A (ru) 2019-10-10
CN108348552A (zh) 2018-07-31
TWI759270B (zh) 2022-04-01
IL257929A (en) 2018-05-31

Similar Documents

Publication Publication Date Title
IL283733A (en) Methods for treating cancer using activated t cells
GB2607227B (en) Viral methods of T cell therapy
HK1251408A1 (zh) 治療癌症的方法
ZA201804227B (en) Methods of treating cancer
IL281293A (en) Methods of treating hyperalgesia
EP3313401A4 (en) PROCESS FOR TREATING EPITHELOID CELL TUMORS
HK1257882A1 (zh) 通過t細胞療法來治療多發性骨髓瘤和漿細胞性白血病的方法
HK1254397A1 (zh) 通過t細胞療法治療cmv視網膜炎的方法
IL256207B (en) Methods for treating multiple sclerosis
HK1246655A1 (zh) 治療不育的方法
HK1259347A1 (zh) 治療結腸炎的方法
ZA201807431B (en) Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
EP3325006A4 (en) METHOD FOR TREATING CD166-EXPRESSIVE CANCER
HK1250145A1 (zh) 治療多發性骨髓瘤的組合物和方法
HK1249866A1 (zh) 用他塞利昔布進行治療的方法
IL267231A (en) Methods of treating diseases associated with ilc2 cells
IL262951A (en) Methods of drug therapy associated with ilc3 cells
HK1245107A1 (zh) 多發性骨髓瘤的羅尼哌他組合治療
PT3261661T (pt) Menotropina para tratar a infertilidade